JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

To construct and validate a risk score model of angiogenesis-related genes to predict the prognosis of hepatocellular carcinoma

  • 0Department of Interventional Radiology, The Affiliated Hospital of Guizhou Medical University, No. 9 Beijing Road, Guiyang, 550002, China.
Scientific Reports +

|

February 7, 2025

|

February 7, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

This study developed a prognostic model using 13 angiogenesis-related genes to predict hepatocellular carcinoma (HCC) patient outcomes. The model identifies high-risk patients with poorer prognoses and highlights AEBP1 as a potential therapeutic target for HCC.

Area Of Science

  • Oncology
  • Molecular Biology
  • Bioinformatics

Background

  • Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally.
  • Angiogenesis plays a critical role in HCC progression and metastasis, making angiogenesis-related genes key targets for study.
  • Identifying novel biomarkers for HCC prognosis and treatment is crucial.

Purpose Of The Study

  • To develop a prognostic risk assessment model for HCC based on angiogenesis-related genes.
  • To investigate the role of specific angiogenesis-related genes (ATP2A3, AEBP1, PNMA1, PLAT) in HCC.
  • To explore AEBP1 as a potential therapeutic target for HCC.

Main Methods

  • Utilized public RNAseq and clinical data from TCGA and GEO databases.
  • Applied Cox and LASSO regression analyses to build and validate a prognostic risk model.
  • Performed Gene Set Variation Analysis (GSVA), immune infiltration analysis (CIBERSORT, ESTIMATE, TIMER), qRT-PCR, and Western blotting.
  • Conducted gene knockout experiments (AEBP1) in HCCLM3 cells.

Main Results

  • A prognostic model based on 13 angiogenesis-related genes was established, differentiating high-risk and low-risk HCC patient groups with distinct survival outcomes.
  • The risk score independently predicted overall survival (OS) in HCC patients.
  • High-risk patients exhibited altered metabolic pathways and a pro-tumorigenic immune microenvironment.
  • Key genes (AEBP1, ATP2A3, PLAT, PNMA1) showed differential expression in HCC tissues, and AEBP1 knockout inhibited HCC cell proliferation, migration, and invasion.

Conclusions

  • A novel risk score model serves as a prognostic biomarker for HCC, potentially guiding personalized treatment strategies.
  • AEBP1 is identified as a promising therapeutic target for hepatocellular carcinoma.

Keywords: